This week was full and frantically busy, and I am not just talking about the three days I drove back and forth to Bridgewater, N.J., for ExL Pharma’s Digital Pharma conference (if you want the quick lowdown on what happened there, you can find the Tweets, from me and many others, under the hashtag #DigPharm). This week, AstraZeneca offered a buyout to all of its sales representatives (and Pharmalot broke the news); Pfizer started handing out layoffs to most of the former Wyeth sales force; FDA sent a warning letter to King Pharmaceuticals over two video news releases about the pain drug Embeda; the Government Accountability Office released a report that says FDA doesn’t debar researchers quickly enough when they have been found to have conflicts of interest (another hat tip here to Ed Silverman and Pharmalot); FDA has delayed its decision on whether to approve Amgen’s denosumab; and drugmakers were found to be the biggest contributors to the National Alliance on Mental Illness.